Capricor Therapeutics Inc (NASDAQ:CAPR) Given Consensus Rating of “Buy” by Brokerages

Shares of Capricor Therapeutics Inc (NASDAQ:CAPR) have earned a consensus rating of “Buy” from the six brokerages that are covering the stock, MarketBeat reports. Six research analysts have rated the stock with a buy recommendation. The average 12 month target price among brokerages that have issued ratings on the stock in the last year is $34.50.

A number of analysts have weighed in on CAPR shares. Cantor Fitzgerald restated an “overweight” rating and set a $30.00 target price on shares of Capricor Therapeutics in a report on Thursday, March 20th. HC Wainwright reissued a “buy” rating and issued a $77.00 price target on shares of Capricor Therapeutics in a research report on Monday, March 17th.

Capricor Therapeutics Price Performance

CAPR stock opened at $9.06 on Friday. Capricor Therapeutics has a 1-year low of $3.52 and a 1-year high of $23.40. The business has a 50-day moving average price of $13.50 and a 200 day moving average price of $15.02. The company has a market capitalization of $413.82 million, a P/E ratio of -8.55 and a beta of 4.09.

Capricor Therapeutics (NASDAQ:CAPR) last posted its quarterly earnings results on Wednesday, March 19th. The biotechnology company reported ($0.16) EPS for the quarter, beating the consensus estimate of ($0.31) by $0.15. Capricor Therapeutics had a negative net margin of 146.86% and a negative return on equity of 112.95%. The business had revenue of $11.13 million during the quarter, compared to analyst estimates of $9.87 million. On average, analysts anticipate that Capricor Therapeutics will post -1.21 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently added to or reduced their stakes in CAPR. Vanguard Group Inc. boosted its holdings in Capricor Therapeutics by 44.4% in the fourth quarter. Vanguard Group Inc. now owns 2,276,784 shares of the biotechnology company’s stock worth $31,420,000 after acquiring an additional 700,243 shares in the last quarter. Farallon Capital Management LLC acquired a new stake in Capricor Therapeutics in the 4th quarter worth approximately $31,056,000. Geode Capital Management LLC grew its position in Capricor Therapeutics by 37.8% during the 4th quarter. Geode Capital Management LLC now owns 879,468 shares of the biotechnology company’s stock worth $12,139,000 after purchasing an additional 241,279 shares during the last quarter. Altium Capital Management LLC increased its stake in Capricor Therapeutics by 150.5% during the 4th quarter. Altium Capital Management LLC now owns 714,000 shares of the biotechnology company’s stock valued at $9,853,000 after purchasing an additional 429,000 shares in the last quarter. Finally, Woodline Partners LP acquired a new position in Capricor Therapeutics during the 4th quarter valued at approximately $8,693,000. 21.68% of the stock is currently owned by hedge funds and other institutional investors.

About Capricor Therapeutics

Capricor Therapeutics, Inc (NASDAQ:CAPR) is a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class biological therapeutics for the treatment of rare disorders. Capricor’s lead candidate, CAP-1002, is an allogeneic cell therapy that is currently in clinical development for the treatment of Duchenne muscular dystrophy.